877149-80-9

Basic information

• Product Name: N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine
• Synonyms: N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine;diMethyl({2-[4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]ethyl})aMine;N,N-diMethyl-2-(4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethanaMine;1H-Pyrazole-1-ethanaMine, N,N-diMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl);N,N-dimethyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]ethanamine
• CAS NO: 877149-80-9
• Molecular Formula: C₁₃H₂₄BN₃O₂
• Molecular Weight: 265.15956
• Mol File: 877149-80-9.mol

Chemical Properties

• Boiling Point: 365.765°C at 760 mmHg
• Flash Point: 175.009°C
• Appearance: /
• Density: 1.041g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.508
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine(877149-80-9)
• EPA Substance Registry System: N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine(877149-80-9)

Safety Data

• Hazardous Substances Data: 877149-80-9(Hazardous Substances Data)

Usage

Uses

Used in Coordination Chemistry:
N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine is used as a ligand in coordination chemistry for its ability to form stable complexes with metal ions. This property is valuable for studying the structure, properties, and reactivity of metal complexes, as well as for developing new materials with specific functions.
Used in Catalysis:
In the field of catalysis, N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine serves as a catalyst or a catalyst precursor, facilitating various chemical reactions. Its unique structure allows it to activate and stabilize reactive intermediates, enhancing the efficiency and selectivity of catalytic processes.
Used in Pharmaceutical Industry:
N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine is used as a building block or intermediate in the synthesis of pharmaceutical compounds. Its structural features can be incorporated into drug molecules to modulate their biological activity, potentially leading to the development of new therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Industry:
In agrochemicals, N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine is utilized in the design and synthesis of novel agrochemicals, such as pesticides and herbicides. Its unique structural elements can be exploited to enhance the activity and selectivity of these compounds, contributing to more effective and environmentally friendly agricultural practices.
Used in Material Science:
N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine is employed in material science for the development of new materials with specific properties. Its incorporation into polymers, coatings, or other materials can impart unique characteristics, such as improved thermal stability, enhanced mechanical properties, or specific optical or electronic behaviors.
Used in Medicinal Chemistry Research:
In medicinal chemistry, N,N-DiMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-ethanaMine is of interest for its potential biological activities. Researchers are exploring its interactions with biological targets, such as enzymes, receptors, or other proteins, to understand its pharmacological effects and potential therapeutic applications.

InChI:InChI=1/C13H24BN3O2/c1-12(2)13(3,4)19-14(18-12)11-9-15-17(10-11)8-7-16(5)6/h9-10H,7-8H2,1-6H3

Upstream product

• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 107-99-3 2-(dimethylamino)ethyl chloride 
• 2862-39-7 2-(dimethylamino)ethyl bromide hydrobromide 
• 73183-34-3 bis(pinacol)diborane 
• 847818-54-6 2-(4-bromo-1H-pyrazol-1-yl)-N,N-dimethylethanamine 
• 4584-46-7 (2-chloroethyl)dimethylamine hydrochloride 
• 877149-79-6 1-(2-chloroethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 124-40-3 dimethyl amine 

Downstream Products

• 1430727-52-8 5-(5-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-2',4'-difluorobiphenyl-3-amine 
• 1430723-39-9 N-(5-(5-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-2',4'-difluorobiphenyl-3-yl)methanesulfonamide 
• 1430723-38-8 N-(5-(5-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-2',4'-difluorobiphenyl-3-yl)acetamide 

Relevant articles and documents

AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention discloses an aminopyridine compounds, a preparation method and use thereof, particularly the aminopyridine compounds of formula (I), pharmaceutical compositions containing the same, the method for preparing the same and the use thereof in the prophylaxis or treatment of an adenosine A2a receptor related disease.

Design, synthesis, and structure activity relationship (SAR) studies of novel imidazo[1,2-a] pyridine derivatives as Nek2 inhibitors

Never in mitosis (NIMA) related kinase 2 (Nek2) is involved in multiple cellular processes such as cell cycle checkpoint regulation, cell division, DNA damage response and cell apoptosis. Nek2 has been reported to be overexpressed in various tumors and correlated with poor prognosis. Herein, a series of imidazo[1,2-a] pyridines Nek2 inhibitors were designed, synthesized, and their biological activities were investigated. Besides, structure activity relationship analysis of these compounds were performed in the MGC-803 cell. The screening results are promising, and compound 28e shows good proliferation inhibitory activity with an IC50 of 38 nM. The results would be helpful to design and develop more effective Nek2 inhibitors for the treatment of gastric cancer.

PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7

The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.

PYRAZOLOPYRIMIDINE DERIVATIVES

The present invention covers Pyrazolopyrimidine compounds of general formula (I), in which n, o, X, Y, R, Q, R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds u

Imidazo[1,2-a]pyridine compound, and preparation method and applications thereof

The invention discloses an imidazo[1,2-a]pyridine compound, and a preparation method and applications thereof. The imidazo[1,2-a]pyridine compound can inhibit the activity of NEK2 kinases as an NEK2 micro-molecular inhibitor with a novel structure. The in

HETEROARYL COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF

The present invention provides herein is a heteroaryl compound or a stereoisomer, a geometric isomer, a tautomer, a racemate, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, as well as a pharmaceutical composition containing the compound disclosed herein. The present invention also provides herein is use of the compound or the pharmaceutical composition thereof disclosed herein in the manufacture of a medicine for treating autoimmune diseases or proliferative diseases.

PROTEIN KINASE INHIBITORS

A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

PYRAZINE DERIVATIVES AS FGFR INHIBITORS

The present invention relates to pyrazine derivatives, and pharmaceutical compositions including the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS

The present invention provides substituted 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly NAMPT inhibitors and in which R1 R2, Y, X, "Het" and "p" have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salts or stereoisomers or N-oxide thereof.

USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS

The present application provides methods of treating PI3Kδ related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.